1015P Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1 negative or weakly positive advanced non-small cell lung cancer after disease progression on platinum-based therapy: WJOG10317L study (EMERALD)

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 33; pp. S1017 - S1018
Main Authors Zenke, Y., Niho, S., Nakamura, A., Okamoto, T., Hara, S., Akazawa, Y., Hosomi, Y., Hayashi, H., Teraoka, S., Yokoyama, T., Ozaki, T., Ueno, K., Gyotoku, H., Misumi, T., Nakagawa, K., Yamamoto, N., Tsuboi, M.
Format Journal Article
LanguageEnglish
Published 01.09.2022
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
DOI:10.1016/j.annonc.2022.07.1141